Oklahoma Senate Bill SB249

Oklahoma 2023 Regular Session

• Introduced: 2/6/23
• Refer: 2/7/23
• Report Pass: 2/9/23
• Engrossed: 3/1/23
• Refer: 3/29/23
• Report Pass: 4/4/23
• Enrolled: 4/20/23
• Vetoed: 4/26/23
• Override: 5/26/23
• Passed: 5/26/23

Caption

Controlled dangerous substances; defining term; broadening hospice exception from electronic prescription requirement. Emergency.

Impact

The bill has notable implications for state laws, particularly regarding the regulations surrounding prescriptions for controlled dangerous substances. By extending the exceptions to the electronic prescription requirement for hospice services, SB249 addresses the need for timely access to critical medications for terminally ill patients. This change expands the flexibility of practitioners and pharmacies in the administration of such prescriptions, particularly in emergency or sensitive situations.

Summary

Senate Bill 249 is an act that amends various sections of the Uniform Controlled Dangerous Substances Act. It primarily focuses on definitions, particularly broadening the exceptions related to hospice care from the electronic prescription requirements. This bill aims to simplify the process for dispensing controlled substances to patients in hospice and similar settings, recognizing the unique circumstances under which these medications may need to be provided spontaneously and efficiently.

Sentiment

The overall sentiment surrounding SB249 appears favorable as it is seen as a necessary legislation responding to the unique needs of patients receiving hospice care. Supporters argue that the amendments will ensure that patients have timely access to essential medication while minimizing bureaucratic barriers. Conversely, discussions around the bill acknowledge the potential concerns regarding abuse or misuse of controlled substances, although the bill specifically aims to safeguard against such risks.

Contention

While SB249 generally enjoys support, there may be contentions regarding the potential for increased prescriptions outside of typical electronic monitoring protocols. Policymakers have to balance the urgent needs of patient care against the risks of enabling easier access to controlled substances that could be misused. Stakeholders, including healthcare providers and regulatory bodies, will likely monitor the implementation of these changes closely.